Navigation Links
Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
Date:1/8/2014

istorical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to progress with and completion and potential success of the EPIC study, prospects for MST-188 in sickle cell disease, and the Company's development plans for MST-188 in heart failure and acute limb ischemia, including the timing of initiation of any clinical studies.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future studies of MST-188 and the risk that MST-188 may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including EPIC; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of any planned phase 2 clinical study of MST-188; the potential that, even if clinical studies of MST-188 in one indication are successful, clinical studies in another indication may not be successful; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the Company's reliance on contract research organizations (CROs), contract manufacturing orga
'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
2. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
3. Dr. Seth Rudnick Joins G1 Therapeutics as Executive Chairman
4. Advinus Therapeutics, a TATA Enterprise, Meets Year 1 Milestone in Drug Discovery Alliance
5. Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
6. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
7. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
8. PTC Therapeutics To Present At The J.P. Morgan Healthcare Conference
9. Mast Therapeutics Announces Positive Data In Model Of Heart Failure
10. Moderna Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
11. Aratana Therapeutics Acquires Okapi Sciences NV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... 8, 2011 INNOPHARMA LLC announced ... for levetiracetam injection (the generic equivalent of Keppra® injection from ... injectable drug, INNOPHARMA entered into a license agreement with X-GEN ... About INNOPHARMA: INNOPHARMA ...
... 8, 2011 Echo Therapeutics, Inc. (Nasdaq: ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, today announced the receipt of notices of issuance ... notices of registration for the trademarks PRELUDE and SYMPHONY. ...
Cached Medicine Technology:Echo Therapeutics Announces Multiple Patents and Trademark Grants 2Echo Therapeutics Announces Multiple Patents and Trademark Grants 3
(Date:12/19/2014)... Colorado (PRWEB) December 20, 2014 It’s very ... travel is something that is put to the wayside until ... who still have that travel “itch” and that burning desire ... Montrose accommodates families on their journey to Telluride with a ... get visitors to and from the resort, and ensure that ...
(Date:12/19/2014)... 19, 2014 The Plantrician ... developing educational events, tools and resources for healthcare ... School , the world’s leading online cooking school, ... human being needs: Culinary Rx. As an online ... Culinary Rx, scheduled for debut spring 2015, will ...
(Date:12/19/2014)... These vanadium reserves are mostly found in China, ... of vanadium were produced globally in 2013, up 11% ... 6.7% AAGR during the period from 2001 to 2013, ... largest consumer, accounted for more than 90% of total ... the chemical industry. , View Full Report at ...
(Date:12/19/2014)... research warns parents that buying an older car for their teens ... teen drivers killed in the United States between 2008 and 2012 ... often lacked important safety features that are available on newer cars, ... crashes were in cars at least six years old, 34 percent ... in cars 11 to 15 years old, and 17 percent were ...
(Date:12/19/2014)... drug users who also use cocaine and amphetamines have ... users, a new study finds. "We know that ... attempt and completed suicide," Didier Jutras-Aswad, a psychiatry professor ... news release. "However, there are many different profiles of ... users were actually more likely to attempt suicide." ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2
... The leading medical ... shorter working hours for junior doctors. , ... London (PRWeb UK) April 23, 2010 -- HCL Thames Medics , the ... said today that greater use of flexible and locum doctors is vital for ...
... ... Team Up Once Again For Annual Charity Race Across The Golden Gate Bridge, , ... (PRWEB) April 22, 2010 -- Over ... race,s reputation as one of San Francisco,s most unique community-oriented and volunteer organized races. ...
... investigate whether there is a link between the use of ... The cohort study on mobile communications (COSMOS) forms part of ... study will run for 20-30 years and will follow the ... European countries. The UK arm of COSMOS is being led ...
... cancer and other diseases, precise analysis of specific proteins ... theTechnische Universitaet Muenchen (TUM), together with Fujitsu Laboratories of ... only recognizes proteins that are characteristic for specific diseases, ... through the influence of disease or drugs. ...
... April 21, 2010 Although genetics is the ... genes affect intelligence remains largely unknown. A multi-institution team ... USTAR researcher has found that the brain gene STX1A ... displayed by patients with Williams Syndrome (WS). The study ...
... for a long time that children with Down syndrome tend ... other children. But pediatricians needing to record growth milestones at ... based on data collected more than 25 years ago. Since ... care of children with Down syndrome. In addition, the demographics ...
Cached Medicine News:Health News:HCL Thames Medics says more locum doctors could help address European Working Time Directive shortage 2Health News:The 26th Running of San Francisco's Presidio 10 Race Was a Win For Local Charities, the Community and the Environment 2Health News:The 26th Running of San Francisco's Presidio 10 Race Was a Win For Local Charities, the Community and the Environment 3Health News:Health impacts of mobile phone use to be explored in huge new study 2Health News:Health impacts of mobile phone use to be explored in huge new study 3Health News:Biosensor chip enables high-sensitivity protein analysis for disease diagnosis 2Health News:Study of Williams syndrome patients reveals specific gene's role in intelligence 2Health News:Study of Williams syndrome patients reveals specific gene's role in intelligence 3Health News:Nutrition researchers to develop new growth charts for children with Down syndrome 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and ... sample inoculation. With these slides, perform QC ... ,Laboratories enhance their education and training programs ... and interpretation, all on one slide! KWIK-QC ...
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Each slide contains a high yield of concentrated C. parvum oocysts within the positive control well. A negative control well is also included....
Medicine Products: